Heska Corp (NASDAQ:HSKA) has been given a consensus recommendation of “Hold” by the eight analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $102.50.
HSKA has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Heska from a “hold” rating to a “buy” rating and set a $101.00 price objective on the stock in a research report on Thursday, January 10th. Canaccord Genuity reissued a “buy” rating and set a $118.00 price objective on shares of Heska in a research report on Wednesday, February 20th. Sidoti downgraded shares of Heska from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 26th. Benchmark downgraded shares of Heska from a “buy” rating to a “hold” rating in a research report on Wednesday, February 27th. Finally, B. Riley cut their price objective on shares of Heska from $93.00 to $87.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 27th.
In other news, COO Jason A. Napolitano sold 4,829 shares of the firm’s stock in a transaction dated Wednesday, January 16th. The shares were sold at an average price of $90.91, for a total transaction of $439,004.39. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 27,329 shares of company stock worth $2,638,829 over the last three months. 15.90% of the stock is currently owned by insiders.
NASDAQ:HSKA opened at $85.90 on Friday. The stock has a market capitalization of $646.55 million, a PE ratio of 60.49 and a beta of 0.81. Heska has a 1-year low of $71.60 and a 1-year high of $114.50.
Heska (NASDAQ:HSKA) last released its earnings results on Tuesday, February 26th. The medical research company reported $0.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.76 by ($0.32). Heska had a return on equity of 9.87% and a net margin of 4.59%.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Featured Story: What are the advantages of the Stochastic Momentum Index?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.